Trial Profile

Phase 2 study assessing EDP 235 in acute or long COVID 19

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EDP-235 (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

11 May 2023 New trial record
08 May 2023 According to Enanta Pharmaceuticals media release, the company is focusing on partnership opportunities for a different Phase 2 study in acute or long COVID that could further demonstrate the efficacy of EDP-235.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com